In a viewpoint published in JAMA Psychiatry , experts from Columbia University wrote that placebo-controlled, relapse prevention studies for schizophrenia should no longer be conducted; instead, trials should use active comparators that would protect patients from relapse and offer data on the comparative effectiveness of the drugs involved.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review | 1 | 397 | August 22, 2015 | |
| These Clinical Trials For Schizophrenia May Be Killing Patients | 3 | 538 | September 10, 2016 | |
| One Experiment With new APs I Find Questionable | 2 | 409 | March 30, 2016 | |
| The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics | 0 | 641 | August 22, 2015 | |
| Importance of Relapse Prevention in Schizophrenia | 26 | 637 | December 26, 2018 |